|
|
Post by #NoMoreNeedles on Feb 27, 2018 4:46:15 GMT -5
Servier could be a fantastic partner, check out their coverage and compare the maps Mike udpated recently: servier.com/en/our-products/our-servier-drugs/. Servier: We are an international and independent pharmaceutical company governed by a non-profit foundation. |
|
|
|
Post by akemp3000 on Feb 27, 2018 5:14:05 GMT -5
Servier could be a fantastic partner, check out their coverage and compare the maps Mike udpated recently: servier.com/en/our-products/our-servier-drugs/. Servier: We are an international and independent pharmaceutical company governed by a non-profit foundation. Interesting. Had not heard of them. 140 countries sounds good. 94 million patients sounds good...but they're another French company  I'd rather see a variety of partnerships focused on different countries instead of extensive coverage by one company. I think of Biomm in Brazil, Teva in Israel, etc. |
|
|
|
Post by matt on Feb 27, 2018 8:43:29 GMT -5
Servier is a third tier pharma company with mostly traditional drugs, many of which were acquired as family owned pharmaceutical companies disappeared all over Europe. They do have a sizeable footprint, but their ability to market a drug effectively is mostly focused on Europe which should not be surprising. In recent years they have shown an interest in getting away from traditional pharmaceuticals (i.e. low margins, lots of competition) and branch out into newer forms of pharmaceuticals, notably an IL-1B antagonist developed by Xoma.
Servier agreed to fund $50 million of the development cost of the Xoma program, something all the longs here want to see from a partner, but the ask was worldwide rights for all cardiovascular and diabetes indications, and rights to all other indications outside the US and Japan. That was a very expensive deal from Xoma's standpoint. Ultimately, Servier pulled the plug on Xoma, just as Sanofi did on Mannkind, when the clinical results were not what Servier hoped to see.
The moral of the story is that to get a big international deal with lots of up-front money is likely going to cost MNKD dearly in terms of lost market access, and there is no guarantee that the licensee will remain engaged if the results are poor. The Sanofi deal to put up $150 million, funded the operating losses, and still let MNKD retain 35% of the worldwide profit was a great deal even if the results were not what everybody, including Sanofi, would have liked. Servier and other third tier pharma companies do not have the deep pockets of a Sanofi and will drive a much harder bargain out of necessity. Be careful what you wish for.
|
|
|
|
Post by cretin11 on Feb 27, 2018 10:34:20 GMT -5
When is the last time something was announced during a CC that materially and significantly moved the needle?
|
|
|
|
Post by papanigon on Feb 27, 2018 10:40:32 GMT -5
When is the last time something was announced during a CC that materially and significantly moved the needle? I can't recall the last time. Sure would be nice to see a nice big green spike one of these times. |
|
|
|
Post by akemp3000 on Feb 27, 2018 12:56:55 GMT -5
PPS should be green now if big news were forthcoming later today as leaks usually occur that would cause a bump. I'll remain cautiously optimistic of something to inspire green tomorrow.
|
|
|
|
Post by derek2 on Feb 27, 2018 16:05:11 GMT -5
|
|
|
|
Post by tbone on Feb 27, 2018 17:52:50 GMT -5
Where’s the money?
|
|
|
|
Post by peppy on Feb 27, 2018 18:07:45 GMT -5
what exactly is the deal with CVS that Mike was talking about?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 27, 2018 18:09:10 GMT -5
CVS deal lets MNKD get patients from BCBS in CA and HI onto Afrezza. Not a big deal and wont move the needle much.
|
|
|
|
Post by peppy on Feb 27, 2018 18:10:20 GMT -5
CVS deal lets MNKD get patients from BCBS in CA and HI onto Afrezza. Not a big deal and wont move the needle much. california will help. Compound did not see growth in the guidance. |
|
|
|
Post by dreamboatcruise on Feb 27, 2018 18:10:44 GMT -5
what exactly is the deal with CVS that Mike was talking about? A deal with the Pharmacy Benefit Management arm of CVS (Caremark). Means they've agreed on pricing, rebates, etc. Now they have to go to the insurers that use Caremark and convince them to add Afrezza to their formularies. That's my read FWIW. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 27, 2018 18:11:39 GMT -5
what exactly is the deal with CVS that Mike was talking about? A deal with the Pharmacy Benefit Management arm of CVS (Caremark). Means they've agreed on pricing, rebates, etc. Now they have to go to the insurers that use Caremark and convince them to add Afrezza to their formularies. That's my read FWIW. I thought I heard Castagna say it would allow them to go after BCBS business in California and Hawaii. Correct me if I am wrong. Thx, |
|
|
|
Post by mytakeonit on Feb 27, 2018 18:13:54 GMT -5
Yep you got it ... Mike mentioned HAWAII !!! He heard that liane will be eating here and will need Afrezza !
|
|
|
|
Post by dreamboatcruise on Feb 27, 2018 18:13:57 GMT -5
CVS deal lets MNKD get patients from BCBS in CA and HI onto Afrezza. Not a big deal and wont move the needle much. There is still another step of convincing these insurance organizations, such as CA BCBS to add Afrezza to their formularies. I think those two were just examples... though possibly MNKD is hinting at ones they are close to signing on. |
|
I'd rather see a variety of partnerships focused on different countries instead of extensive coverage by one company. I think of Biomm in Brazil, Teva in Israel, etc.
